Lansoy-Kuhn Caroline, Picquenot Jean M, Edet-Sanson Agathe, Mechken Férial, Laberge-Le Couteulx Sophie, Cornic Marie, Vera Pierre
Department of Nuclear Medicine, Henri Becquerel Centre, Rouen University Hospital, Rouen, France.
Nucl Med Commun. 2013 Apr;34(4):340-6. doi: 10.1097/MNM.0b013e32835e59ee.
In patients thyroidectomized for well-differentiated thyroid carcinoma, the correlation between thyroglobulin (Tg) plasma level and F-fluoro-2-deoxy-D-glucose (F-FDG)-PET results is still a matter of debate. We evaluated whether the immunochemical profile of the primary tumour could be used as a predictor of positivity on F-FDG-PET/computed tomography (CT) when recurrence is confirmed.
A total of 26 patients (eight men, 18 women; 51±16 years old) were included. All of the patients had a histologically proven recurrence or a high level of Tg during follow-up and underwent a F-FDG-PET/CT following two intramuscular injections of rhTSH. The F-FDG-PET/CT scans were blindly analysed by three nuclear physicians. The results of the PET scans were classified as true positive, false positive or false negative. Nine antibodies were used for the immunochemical analysis (tissue microarray: hexokinase I, II and III; Tg; vascular endothelial growth factor; and glucose transporter type 1, CD31, CD68 and sodium iodide symporter).
The PET scans were positive for 15 patients and negative for 11 patients. Hexokinase I was expressed in nine of the 26 primary tumours (7/26 for the isoforms). No single molecule expressed in the primary tumours was correlated with the F-FDG-PET/CT results. There was no association of antibody overexpression (clustering) in the primary tumours with the F-FDG-PET/CT results of the recurrences.
In a larger series, we failed to confirm the preliminary results of Hooft and colleagues. This study did not allow for the determination of a single marker expressed in the primary tumours that would be predictive of F-FDG-PET/CT positivity when recurrence is suspected. Therefore, at present, immunochemistry does not appear to be a definitive tool for predicting the results of F-FDG-PET/CT in cases of recurrence.
在因分化型甲状腺癌接受甲状腺切除术的患者中,甲状腺球蛋白(Tg)血浆水平与氟代脱氧葡萄糖(F-FDG)-PET结果之间的相关性仍存在争议。我们评估了在复发得到确认时,原发性肿瘤的免疫化学特征是否可作为F-FDG-PET/计算机断层扫描(CT)阳性的预测指标。
共纳入26例患者(8例男性,18例女性;年龄51±16岁)。所有患者在随访期间均有组织学证实的复发或高水平的Tg,并在两次肌肉注射重组人促甲状腺激素(rhTSH)后接受了F-FDG-PET/CT检查。三位核医学医师对F-FDG-PET/CT扫描结果进行了盲法分析。PET扫描结果分为真阳性、假阳性或假阴性。使用九种抗体进行免疫化学分析(组织芯片:己糖激酶I、II和III;Tg;血管内皮生长因子;以及葡萄糖转运蛋白1型、CD31、CD68和钠碘同向转运体)。
PET扫描结果显示,15例患者为阳性,11例患者为阴性。26例原发性肿瘤中有9例表达己糖激酶I(异构体为7/26)。原发性肿瘤中表达的单一分子均与F-FDG-PET/CT结果无关。原发性肿瘤中抗体过表达(聚集)与复发时的F-FDG-PET/CT结果之间无关联。
在更大的系列研究中,我们未能证实胡夫特及其同事的初步结果。本研究未能确定原发性肿瘤中表达的单一标志物可预测怀疑复发时F-FDG-PET/CT的阳性结果。因此,目前免疫化学似乎不是预测复发时F-FDG-PET/CT结果的决定性工具。